SCHEDULE: Scipher Medicine Amends Note Agreement, Extends Closing Deadline

Scipher Medicine Corporation has amended its Convertible Note Purchase and Investment Obligation Agreement, extending the Strategic Transaction Closing Deadline and introducing new convertible note issuances.

Summary

• Scipher Medicine Corporation has entered into Amendment No. 2 to its Convertible Note Purchase and Investment Obligation Agreement, dated July 17, 2026.
• The amendment extends the Strategic Transaction Closing Deadline from July 31, 2026, to March 31, 2027.
• It also introduces a new issuance of convertible notes in July 2026 and increases the Strategic Investment Pro Rata Amounts for investors.
• A new Section 1.10 details the sale and issuance of July 2026 Notes, with an initial closing around July 21, 2026.
• Provisions are included for defaulting purchasers, where their notes may be subordinated or cancelled.
• The agreement also amends definitions related to convertible note pro rata amounts and excess investment amounts.
• Amendment No. 3, dated October 29, 2026, further amends the agreement to provide for a new issuance of convertible notes in October 2026 and addresses ATM Shares and pay-to-play mechanics.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, indicating continued investor confidence and strategic adjustments to facilitate a significant transaction, though the extended timeline introduces some uncertainty.

Positives

• Extension of the Strategic Transaction Closing Deadline to March 31, 2027, provides more time to complete the transaction.
• Introduction of new convertible note issuances in July and October 2026 demonstrates continued investor commitment and provides additional capital.
• Increase in Strategic Investment Pro Rata Amounts for investors indicates potential for larger investments.
• The agreement clarifies the treatment of defaulting purchasers, ensuring that non-defaulting purchasers' positions are protected.

Negatives

• The extension of the closing deadline from July 31, 2026, to March 31, 2027, indicates potential delays or complexities in the strategic transaction.
• Provisions for defaulting purchasers and the potential subordination or cancellation of their notes suggest a risk of some investors not fulfilling their obligations.
• The complexity of the amended definitions and calculations for various pro rata amounts could lead to confusion or disputes.

Risks

• The PIPE transaction may not be consummated by March 31, 2027, in which case investment obligation funds will be returned.
• If a purchaser fails to meet their obligations for the July Notes or the Strategic Transaction, their notes may be automatically amended to be junior in all respects to notes held by non-defaulting purchasers, potentially leading to cancellation for no consideration.
• The strategic transaction could be terminated after a definitive agreement is entered into, leading to the return of investment obligation funds.
• The company's ability to secure the full amount of financing through subsequent closings of the Notes is subject to purchaser participation.

Future Outlook

The company has extended the Strategic Transaction Closing Deadline to March 31, 2027, and has arranged for new issuances of convertible notes in July and October 2026, indicating ongoing efforts to secure financing and complete a strategic transaction. The success of these efforts is contingent on the approval of the Board and the participation of investors.

Management Comments

• The Board of Directors has the authority to determine the Strategic Transaction Closing Deadline.
• Management has agreed to terms that allow for the extension of deadlines and the issuance of new notes to facilitate the strategic transaction.

Industry Context

StockSavvy.ai notes that extending closing deadlines and issuing new convertible notes are common strategies for companies navigating complex M&A or strategic transactions, especially in the biotech sector where financing and regulatory approvals can be lengthy. This indicates Scipher Medicine is actively managing its capital structure and transaction timelines.

Comparison to Industry Standards

• Extending transaction closing dates is a common practice when complex due diligence, regulatory approvals, or financing arrangements require additional time. Many biotech M&A deals have seen similar extensions.
• The use of convertible notes as a financing mechanism is standard in the venture capital and biotech industries, particularly for companies in development stages or undergoing significant strategic shifts.
• The structure of the agreement, involving 'Requisite Purchasers' controlling amendments, is typical for syndicated financing rounds, ensuring a majority of investors are aligned with changes.

Stakeholder Impact

• Shareholders: The extension of the closing deadline and the issuance of new convertible notes may impact the dilutive effect and the timeline for the strategic transaction, potentially affecting share value.
• Investors/Purchasers: The amendments provide clarity on future investment obligations and the treatment of defaulting purchasers, while also extending the timeline for their investment to yield returns.
• Creditors: The issuance of new unsecured convertible notes increases the company's indebtedness, which could affect its financial leverage and standing with existing creditors.

Next Steps

• The company will proceed with the July 2026 and October 2026 convertible note closings.
• The company will continue to work towards the Strategic Transaction, with a new closing deadline of March 31, 2027.
• Purchasers will fulfill their Investment Obligations subject to the terms and conditions of the amended agreement.
• The company will invest in Chemomab's ATM Program by November 3, 2026.

Key Dates

Recommendation

The amendments indicate ongoing strategic maneuvers and continued investor support, which are positive. However, the repeated extensions of the closing deadline suggest potential hurdles or complexities in the underlying strategic transaction, introducing uncertainty. Therefore, a 'hold' recommendation is appropriate pending further clarity on the strategic transaction's progress and ultimate completion.

Keywords

Convertible Note, Strategic Transaction, Amendment, Investment Obligation, PIPE, Closing Deadline, Financing, Merger Agreement